GlassScriptPhysician profile
Kofi-Ann Mcdermott
NPI 1427821990
$2,682.64
in general payments reported to CMS, 2019-2025
30 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $722 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.41 |
| Education | $311.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $398.68 | 2024-2025 | Rybrevant, Darzalex, Carvykti |
| Incyte Corporation | $235.61 | 2024-2025 | Zynyz, Monjuvi |
| Genzyme Corporation | $232.68 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $181.47 | 2024-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $149.17 | 2025 | |
| Karyopharm Therapeutics INC. | $146.04 | 2024-2025 | Xpovio |
| Beone Medicines USA, INC. | $140.30 | 2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $135.50 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $126.44 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $125.89 | 2025 | |
| Genentech USA, INC. | $110.31 | 2024-2025 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Daiichi Sankyo INC. | $79.47 | 2024-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $69.22 | 2024-2025 | |
| Pharmaessentia USA Corporation | $55.88 | 2025 | Besremi |
| Emd Serono, INC. | $55.46 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $48.21 | 2025 | Reblozyl |
| Tempus Ai, INC | $42.38 | 2024 | |
| Glaxosmithkline, LLC. | $41.81 | 2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $37.93 | 2024-2025 | |
| Lilly USA, LLC | $37.70 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Coherus Oncology, INC. | $36.80 | 2024-2025 | Udenyca |
| Alexion Pharmaceuticals, INC. | $33.12 | 2025 | Ultomiris |
| Adaptive Biotechnologies Corporation | $26.89 | 2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2025 | |
| Exelixis INC. | $21.64 | 2025 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $20.53 | 2025 | Empaveli |
| Puma Biotechnology, INC. | $19.57 | 2024 | |
| Legend Biotech USA INC. | $17.97 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $17.20 | 2024 | Libtayo |
| Acrotech Biopharma INC. | $17.06 | 2025 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kofi-Ann Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.